may result in market up by high-single-digits in 2014. Weight-loss stocks [ WTW, NTRI ] and diet-drug stocks [ VYUS, ARNA ] have been hit with company specific issues [ the obesity problem hasn’t gone away after all ] but they may not have bottomed

appearing to rebound, it’s little wonder that Ellie Mae has found strong demand for its product. Arena Pharma (NASDAQ: ARNA ): is up roughly 367 percent in 2012. It’s been overshadowed in the biotech world by Sarepta, but more than tripling in a single